Fibrinolysis

• 

  Subject Areas on Research

  • A comparative study of crosslinked and noncrosslinked fibrin from the major classes of vertebrates. 
  • A marriage of enhancement: fibrinolysis and conjunctive therapy. 
  • Activated human plasma carboxypeptidase B is retained in the blood by binding to alpha2-macroglobulin and pregnancy zone protein. 
  • Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. 
  • After fibrinolysis: is cardiac catheterization the answer? 
  • An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age. 
  • Analyzing fibrin clot structure using a microplate reader. 
  • Anaphylactic and anaphylactoid reactions. A review. 
  • Angiotensin-converting enzyme inhibition alters the inflammatory and fibrinolytic response to cardiopulmonary bypass in children. 
  • Annexin 2/factor xa-mediated signal transduction. 
  • Antifibrinolytic Therapy and Perioperative Considerations. 
  • Aprotinin versus tranexamic acid: the controversy continues. 
  • Atrophie blanche. A disorder associated with defective release of tissue plasminogen activator. 
  • Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. 
  • Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI). 
  • Blood coagulation and idiopathic thromboembolism among fertile women. 
  • Blood coagulation: hemostasis and thrombin regulation. 
  • Bolus fibrinolysis: risk, benefit, and opportunities. 
  • Carbon monoxide releasing molecule-2 enhances α2-antiplasmin activity. 
  • Cardiac constriction following aorta-to-coronary bypass surgery. 
  • Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease. 
  • Challenges for providing effective hemostasis in surgery and trauma. 
  • Clopidogrel does not induce fibrinolysis in healthy subjects. 
  • Coagulation 2006: a modern view of hemostasis. 
  • Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass. 
  • Coagulation in Liver Disease. 
  • Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. 
  • Cross-linking of fibrin by fibrin=stabilizing factor. 
  • Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. 
  • DDAVP--the multipotent drug in patients with coagulopathies. 
  • Decreased fibrinolytic activity in porcine-to-primate cardiac xenotransplantation. 
  • Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. 
  • Disseminated intravascular coagulation (DIC): an approach. 
  • Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. 
  • Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. 
  • Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. 
  • Effect of two doses of tranexamic acid on fibrinolysis evaluated by thromboelastography during cardiac surgery: a randomised, controlled study. 
  • Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation. 
  • Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review. 
  • Endovascular stroke intervention in young patients with large vessel occlusions. 
  • Exploration of rapid bedside monitoring of coagulation and fibrinolysis parameters during thrombolytic therapy. 
  • Factors and inhibitors of blood coagulation and fibrinolysis in acute nonlymphoblastic leukaemia. 
  • Fibrinolysis and fibrinogenolysis by Val442-plasmin. 
  • Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 2. 
  • Fibrinolysis for acute myocardial infarction: the future is here and now. 
  • Fibrinolysis in LPS-induced chronic airway disease. 
  • Fibrinolysis vs disseminated intravascular coagulation. 
  • Fibrinolytic abnormalities in two different cutaneous manifestations of venous disease. 
  • Fibrinolytic response and oral contraceptive associated thromboembolism. 
  • Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. 
  • Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. 
  • Haemodilution-induced profibrinolytic state is mitigated by fresh-frozen plasma: implications for early haemostatic intervention in massive haemorrhage. 
  • Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. 
  • Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. 
  • Hyaluronan fragments induce plasminogen activator inhibitor-1 and inhibit urokinase activity in mouse alveolar macrophages: a potential mechanism for impaired fibrinolytic activity in acute lung injury. 
  • Hypercoagulable states in cardiovascular disease. 
  • Iliac vein thrombosis: feasibility assessment of randomized controlled trials of endovascular pharmacomechanical thrombolysis. 
  • In vitro preparation of nonenzymatically glucosylated human transferrin, alpha 2-macroglobulin, and fibrinogen with preservation of function. 
  • Induction of tissue-type plasminogen activator and 72-kDa type-IV collagenase by ionizing radiation in rat astrocytes. 
  • Infant cardiopulmonary bypass: a procoagulant state. 
  • Influence of changes in lifestyle on fibrinolytic parameters and recurrence rate in patients with venous thromboembolism. 
  • Intraocular injection of recombinant hirudin to prevent experimental postoperative fibrin. 
  • Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. 
  • Lipoprotein (a) in the regulation of fibrinolysis. 
  • Lipoprotein (a) regulates plasmin generation and inhibition. 
  • Lipoprotein (a): purification and kinetic analysis. 
  • Lipoprotein(a) and its role in atherothrombotic disease. 
  • Lipoprotein(a) inhibits plasminogen activation in a template-dependent manner. 
  • Management of hyperglycemia in acute stroke: how, when, and for whom? 
  • Massive transfusion coagulopathy. 
  • Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin. 
  • Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. 
  • Myocardial ischemia correlates with reduced fibrinolytic activity following peripheral vascular surgery. 
  • Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. 
  • Ozone exposure is associated with acute changes in inflammation, fibrinolysis, and endothelial cell function in coronary artery disease patients. 
  • Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. 
  • Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. 
  • Pathophysiological Response to Trauma-Induced Coagulopathy: A Comprehensive Review. 
  • Physical conditioning and fibrinolysis. 
  • Physical conditioning augments the fibrinolytic response to venous occlusion in healthy adults. 
  • Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits. 
  • Platelet-mediated thrombolysis in patients with δ-storage pool deficiency: a thrombelastographic analysis. 
  • Polynitrosylated proteins: characterization, bioactivity, and functional consequences. 
  • Postoperative disseminated intravascular coagulation and fibrinolysis. 
  • Prenatal screening for thrombophilia: the background and the approach. 
  • Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia. 
  • Purification and characterization of a fibrinolytic enzyme of Bacillus subtilis DC33, isolated from Chinese traditional Douchi. 
  • Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Recalibrating Reperfusion Waypoints. 
  • Recombinant hirudin for prevention of experimental postoperative intraocular fibrin. 
  • Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. 
  • Regulation of tissue plasminogen activator in sickle cell anemia. 
  • Release of tissue plasminogen activator and its fast-acting inhibitor in defective fibrinolysis. 
  • Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options. 
  • Role of thrombotic and fibrinolytic alterations in the pathogenesis and treatment of osteonecrosis. 
  • Short- and long-term outcomes of patients with electrocardiographic left ventricular hypertrophy after fibrinolysis for acute myocardial infarction. 
  • Sialic acid content of plasminogen 2 glycoforms as a regulator of fibrinolytic activity. Isolation, carbohydrate analysis, and kinetic characterization of six glycoforms of plasminogen. 
  • Simple and sensitive assay employing stable reagents for quantification of plasminogen activator. 
  • Skeletal muscle dictates the fibrinolytic state after exercise training in overweight men with characteristics of metabolic syndrome. 
  • Streptokinase and human fibronectin share a common epitope: implications for regulation of fibrinolysis and rheumatoid arthritis. 
  • Streptokinase-induced degradation of crosslinked and uncrosslinked clots. 
  • Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis. 
  • The Comparison of the Outcomes between Primary PCI, Fibrinolysis, and No Reperfusion in Patients ≥ 75 Years Old with ST-Segment Elevation Myocardial Infarction: Results from the Chinese Acute Myocardial Infarction (CAMI) Registry. 
  • The biochemistry of haemostasis. 
  • The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. 
  • The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. 
  • The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis. 
  • The intrinsic enzymatic activity of procarboxypeptidase U (TAFI) does not significantly influence the fibrinolytic rate: reply to a rebuttal. 
  • The many faces of the contact pathway and their role in thrombosis. 
  • The rabbit as a model for studies of fibrinolysis. 
  • The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease. 
  • The voltage-dependent anion channel (VDAC) binds tissue-type plasminogen activator and promotes activation of plasminogen on the cell surface. 
  • Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. 
  • Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase. 
  • Thrombolysis and fibrinolytic parameters during heparin treatment of deep vein thrombosis. 
  • Thromboxane A2modulates the fibrinolytic system in glomerular mesangial cells. 
  • Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. 
  • Tissue plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil. 
  • Transport time and care processes for patients transferred with ST-segment-elevation myocardial infarction: the reperfusion in acute myocardial infarction in Carolina emergency rooms experience. 
  • Treatment of mechanical aortic valve thrombosis with heparin and eptifibatide. 
  • Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. 
  • Use of early clopidogrel by reperfusion strategy among patients presenting with ST-segment elevation myocardial infarction. 
  • Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII. 
  • Why is lipoprotein(a) relevant to thrombosis? 
  • epsilon-Aminocaproic acid plasma levels during cardiopulmonary bypass. 
• 

  Keywords of People

  • Hoffman, Maureane, Professor of Pathology, Immunology
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Toth, Cynthia Ann, Joseph A.C. Wadsworth Distinguished Professor of Ophthalmology, Biomedical Engineering